| 영문 | non-Hodgkin lymphoma | 한글 | 비호지킨 림프종 |
|---|---|---|---|
| 설명 | 림프종은 림프절에 생긴 악성 종양으로 백혈병과는 다르다. 백혈병은 골수에서 생긴 림프구성 악성종양이지만, 림프종은 림프조직에서 생긴 림프구성 악성종양이다. 크게 림프종은 2가지로 나눌 수 있는 데, 호지킨병(Hodgkin's lymphoma)과 비호지킨림프종(non-Hodgkin's lymphoma)으로 나눌 수 있다. 또한 비호지킨림프종은 여러 가지의 세포형태에 따라 나누고 있다. 이 병은 단지 림프절뿐만 아니라 지라, 골수, 이외 다른 기관을 침범함으로써 악성이며, 생명에 큰 위협을 준다. 악성림프종의 일종. 전이의 형태가 다양하여, 주위 림프절을 건너뛰어 다른 림프절로 전이하기도 한다. 또한 세포의 형태에 따라 여러 가지 종류가 있으며 대개 치료는 방사선치료와 화학요법을 복합하여 사용한다. |
||
| ECG | Electro-Cardio-Graphy(-Gram); 심전도 = EKG 1. Conducting System Structu... |
|---|---|
| NANB | non-A, non-B [hepatitis] |
| NANBH | non-A, non-B hepatitis |
| non-REM | non-rapid eye movement [sleep] |
| AVP | 1) Active non apeptide(?) 2) Arginine Vaso-Pressin |
| SE | Secretor |
|---|---|
| NANB | C/non-A, non-B |
| NANB | Non-A Non-B Hepatitis |
| NANBH | Non-A Non-B hepatitis |
| non-NMDA | Non-N-Methyl-D-aspartate |
| non-A, non-B, non-C hepatitis | Hepatitis caused by viral organisms other than hepatitis viruses A, B or C. (05 Mar 2000) |
|---|---|
| hepatitis non-A, non-B | <virology> A virus somewhat similar in size to Hepatitis A but has no antigenic cross reaction with either A or B. Many of the cases are in fact hepatitis C and this was the old term for hepatitis C. (20 Sep 2002) |
| non-A, non-B hepatitis | Hepatitis caused by two or more infectious agents not detectable by methods that reveal the presence of hepatitis viruses A and B; one cause, now called type C hepatitis has been identified; may follow blood transfusion and is often seen in chronic renal dialysis patients. Synonym: NANB hepatitis. (05 Mar 2000) |
| non-A, non-B hepatitis virus | Term used to group any of a number of viruses, other than A or B, which cause hepatitis in humans. (05 Mar 2000) |
| secretor | <haematology, physiology> An individual whose bodily fluids (saliva, semen, vaginal secretions) contain a water-soluble form of the antigens of the ABO blood group. Secretors constitute 80% of the population. In forensic medicine, the examination of fluids has enhanced the ability of law enforcement officials to develop identifying information about perpetrators and narrow a field of suspects. (05 Mar 2000) |
| secretor factor | <haematology> The capacity to secrete antigens of the ABO blood group in saliva and other body fluids, controlled by a pair of allelic genes designated Se and se (or S and s), with the Se phenotype dominant to se. The saliva of genotypes SeSe and Sese contains the blood group substances A, B, or H found in their erythrocytes; the saliva of nonsecretors (genotype sese) contains no blood group substance; tests for ABH secretion are useful in genetic linkage and population studies; the secretor phenomenon is also closely associated with the Lewis blood group. (05 Mar 2000) |
| abortifacient agents, non-steroidal | Non-steroidal chemical compounds with abortifacient activity. (12 Dec 1998) |
| acute non-lymphocytic leukaemia | <haematology> A form of leukaemia which is characterised by the proliferation of immature bone marrow precursor cells in the marrow and immature white blood cells (granulocytes) in the bloodstream. Occurs primarily in adults and in infants under 1 year of age. Complications include abnormal bleeding and susceptibility to infections. Symptoms include fatigue, weight loss, fevers, weakness, pallor, bone pains, bleeding gums, nosebleeds, easy bruising, enlarged lymph nodes and joint pains. Trisomy-8 is the most common cytogenetic abnormality observed, followed by monosomy-7 and monosomy-5. Approximately 8% of cases show trisomy-8, mostly in AML (M1), AM (M4) and acute monocytic leukaemia (M5). Many pre-leukaemic conditions, acute non-lymphocytic leukaemia and secondary leukemia show monosomy-7 or deletion of the long arm of chromosome 7. Treatment includes chemotherapy and/or bone marrow transplant. Acronym: ANLL Incidence: 2.5 cases per 100,000 (all ages). Origin: Gr. Haima = blood (07 Apr 1998) |
| analgesics, non-narcotic | Drugs that have principally analgesic, antipyretic, and anti-inflammatory actions. They do not bind to opioid receptors and are not classified under the controlled substances act. (12 Dec 1998) |
| anti-inflammatory agent, non-steroidal | Anti-inflammatory agents that are not steroids. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They are used primarily in the treatment of chronic arthritic conditions and certain soft tissue disorders associated with pain and inflammation. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. Certain nsaids also may inhibit lipoxygenase enzymes or phospholipase c or may modulate T-cell function. (ama drug evaluations annual, 1994, p 1814-5) (12 Dec 1998) |
| auctorum non | Not of authors. (09 Jan 1998) |
| cancer, lymphoma, non-hodgkin's | A lymphoma is a cancer that develops in the lymphatic system. The most common symptom of non-Hodgkin's lymphomas is a painless swelling in the lymph nodes in the neck, underarm, or groin. Non-Hodgkin's lymphomas are diagnosed with a biopsy of an enlarged lymph node. Follow-up examinations are important after lymphoma treatment. Most relapses occur in the first 2 years after therapy. (12 Dec 1998) |
| carcinoma, non-small-cell lung | A heterogeneous aggregate of at least three distinct histological types of lung cancer, including squamous cell carcinoma, adenocarcinoma, and large cell carcinoma. They are dealt with collectively because of the shared properties of poor response to conventional chemotherapy and the potential for cure with surgical resection in a fraction of patients. (12 Dec 1998) |
| Gomori's non-specific acid phosphatase stain | <technique> A method in which formalin-fixed frozen sections are incubated in a substrate containing sodium beta-glycerophosphate and lead nitrate at pH 5.0; the insoluble lead phosphate produced is treated with ammonium sulfide to give a black lead sulfide. (05 Mar 2000) |
| Gomori's non-specific alkaline phosphatase stain | <technique> A calcium-cobalt sulfide method using frozen sections or cold acetone-or formalin-fixed paraffin sections, plus sodium beta-glycerophosphate as a substrate at pH 9.0 to 9.5 with Mg++ as activator; calcium ions precipitate the liberated phosphate, cobalt salt replaces the calcium phosphate, and ammonium sulfide converts the product to a black cobalt sulfide. (05 Mar 2000) |
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|
제품명 |
판매사 |
보험코드 | 성분/함량 | 구분/보험급여 |
|---|